P2Y 12 is a chemoreceptor for adenosine diphosphate (ADP) [5] [6] that belongs to the G i class of a group of G protein-coupled (GPCR) purinergic receptors. [7] This P2Y receptor family has several receptor subtypes with different pharmacological selectivity, which overlaps in some cases, for various adenosine and uridine nucleotides .

ADP binds to and activates the ADP receptor P2Y 12 leading to the inhibition of adenylate cyclases, a decrease in cAMP, PI3 kinase activation, and an increase in AKT phosphorylation. This signaling pathway eventually leads to platelet activation and aggregation.

P2Y receptors are a family of purinergic G protein-coupled receptors, stimulated by nucleotides such as adenosine triphosphate, adenosine diphosphate, uridine triphosphate, uridine diphosphate and UDP-glucose.To date, 8 P2Y receptors have been cloned in humans: P2Y 1, P2Y 2, P2Y 4, P2Y 6, P2Y 11, P2Y 12, P2Y 13 and P2Y 14.

现阶段临床使用的抗动脉粥样硬化药物大多数为p2y 12 拮抗剂，其可与adp受体特异性结合，阻止adp诱导的血小板聚集活化，从而达发挥抗血栓作用 ；同时，有研究所表明p2y 2 受体拮抗剂和p2y 6 拮抗剂也可通过抗炎来发挥抗动脉粥样硬化作用。

2005年5月1日 · On the basis of pharmacologic and genetic studies, it is now accepted that P2Y 1 is required for platelet activation by ADP, whereas P2Y 12 is important in synergizing with P2Y 1 or other G q-coupled receptors to induce platelet activation by ADP and other agonists playing a major role in stabilizing platelet thrombi in vivo.

2011年2月17日 · Defects of P2Y 12 should be suspected when ADP, even at high concentrations (≥ 10μM), is unable to induce full, irreversible platelet aggregation. Tests that evaluate the degree of inhibition of adenylyl cyclase by ADP should be used to confirm the diagnosis.

2023年4月4日 · P2Y 12 is a G-protein-coupled receptor that is activated upon ADP binding. Considering its well-established role in platelet activation, blocking P2Y 12 has been used as a therapeutic strategy for antiplatelet aggregation in cardiovascular disease patients.

Adenosine diphosphate (ADP) receptor inhibitors are a drug class of antiplatelet agents, used in the treatment of acute coronary syndrome (ACS) or in preventive treatment for patients who are in risk of thromboembolism, myocardial infarction or a stroke.

2023年4月4日 · P2Y 12 is a G-protein-coupled receptor that is activated upon ADP binding. Considering its well-established role in platelet activation, blocking P2Y₁₂ has been used as a therapeutic strategy for antiplatelet aggregation in cardiovascular disease patients.

Human purinergic G protein-coupled receptor P2Y 1 (P2Y 1 R) is activated by adenosine 5′-diphosphate (ADP) to induce platelet activation and thereby serves as an important antithrombotic drug target.